Sydney, Australia 16 October 2015 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has been awarded a Business Growth Grant under the Entrepreneurs’ Programme.
The grant, valued at $20,000, will help fund Clarity’s drug development pipeline project plan. The grant will be used to provide funding to engage Dr Ellen Van Dam to assist Clarity in progressing its pharmaceutical assets into the clinic. Dr Van Dam has 20 years’ experience in drug discovery and development, combined with extensive knowledge of cell biology that is well suited to Clarity’s needs.
Dr Van Dam worked in research and development for Pharmaxis and the Garvan Institute, and honed her expertise in commercial development with Brandon Capital at the Medical Research Commercialisation Fund.
Clarity’s Executive Chairman, Dr Alan Taylor, commented “Dr Van Dam is a great resource to bring into our Company at this important stage of our development. Her strong clinical experience and fundamental understanding of biologics will enhance Clarity’s unique expertise in the radiopharmaceutical field as we develop our assets through pre-clinical and clinical development.”
“The Business Growth Grant is part of the Government’s Entrepreneurs’ Programme that is incredibly important for the continued support of translation of science and technology from the bench top through commercialisation. Initiatives like this are fundamental for development of innovative potential in Australia, enabling start-ups to build internal capability, recruit local talent and achieve global competitive advantages,” said Dr Taylor.
